Human IL-33 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.40 pg/ml (50 μl)；4.26 pg/ml (10 μl) |
| Standard Curve Range | 31.25~2000 pg/ml |
| Standard Curve Gradient | 7 Points |
| Number of Incubations | 2 |
| Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0235 | 0.0225 | 0.0230 | |
| 31.25 | 0.1191 | 0.1146 | 0.1169 | 0.0939 |
| 62.50 | 0.2081 | 0.2073 | 0.2077 | 0.1847 |
| 125.00 | 0.3990 | 0.4114 | 0.4052 | 0.3822 |
| 250.00 | 0.7707 | 0.8138 | 0.7923 | 0.7693 |
| 500.00 | 1.5530 | 1.5230 | 1.5380 | 1.5150 |
| 1000.00 | 2.9080 | 2.8210 | 2.8645 | 2.8415 |
| 2000.00 | 4.2280 | 4.2560 | 4.2420 | 4.2190 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 32.6 | 198.3 | 606.2 | 32.7 | 205.7 | 624.8 |
| Standard Deviation | 1.1 | 5.3 | 15.5 | 1.0 | 10.1 | 30.3 |
| Coefficient of Variation(%) | 3.4 | 2.7 | 2.6 | 3.2 | 5.0 | 4.9 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of Human IL-33 into health serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 98% to 108% with an overall mean recovery of 104%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | n.d.-12.90 | 60 | 6.53 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of IL-33 in this assay. No medical histories were available for the donors.
Product Data Sheet
Background: IL-33
IL-33 (Interleukin-33) is released from physically damaged or necrotic cells. It triggers Th2-biased immune cell activation at sites of inflammation as well as regulatory T cell and M2 macrophage expansion. It additionally induces angiogenesis, promotes tumor cell migration and invasion, limits cardiac myocyte hypertrophy, and limits the development of atherosclerotic plaques. IL-33 signals through a receptor complex composed of ST2 and IL-1 RAcP. IL-1 RAcP also associates with IL-1 RI, IL-1 RII, IL-1 R6, and SCF R/c-kit. Soluble isoforms of ST2 and IL-1 RAcP function as decoy receptors that regulate IL-33 bioactivity.
